Global Acute Respiratory Distress Syndrome Treatment Market Size study & Forecast, by Drug Class (Vasoconstrictors, Bronchodilators, Steroids and Antibiotics, Others), By Route of Administration (Oral, Injection, Inhalation), By Distribution Channel (Hosp

Global Acute Respiratory Distress Syndrome Treatment Market Size study & Forecast, by Drug Class (Vasoconstrictors, Bronchodilators, Steroids and Antibiotics, Others), By Route of Administration (Oral, Injection, Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Analysis, 2023-2030

Global Acute Respiratory Distress Syndrome Treatment Market is valued at approximately USD xxx billion in 2022 and is anticipated to grow with a healthy growth rate of more than xx% over the forecast period 2023-2030. Acute Respiratory Distress Syndrome is a medical condition that can occur in response to various underlying causes, such as pneumonia, sepsis, trauma, or inhalation injury. ARDS is characterized by inflammation and fluid buildup in the lungs, which can lead to severe shortness of breath and respiratory failure. The Acute Respiratory Distress Syndrome Treatment market is expanding because of factors such as increasing cases of Preterm birth and growing prevalence of respiratory diseases. Treatment of ARDS typically involves supportive care, such as mechanical ventilation to help with breathing, supplemental oxygen, and medications to manage symptoms and prevent complications. Its prevalence has progressively increased during the last few decades.

According to the World Health Organization, every year, an estimated 15 million babies are born preterm. Furthermore, across countries, the rate of preterm birth ranges from 5% to 18% of babies born. Moreover, more than 90% of extremely preterm babies born in low-income countries die within the first few days of life, yet less than 10% of extremely preterm babies die in high-income settings. Another important component driving space is increased prevalence of respiratory diseases. According to World Health Organization, Asthma affected an estimated 262 million people in 2019 and caused 455 000 deaths. In addition, Chronic obstructive pulmonary disease is the third leading cause of death worldwide, causing 3.23 million deaths Nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries in 2019. Also, increasing demand for diagnosis and rising technological advancement in medical testing devices would create a lucrative growth prospectus for the market over the forecast period. However, the high cost of Acute Respiratory Distress Syndrome Treatment stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Acute Respiratory Distress Syndrome Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to technological advancements and the availability of numerous cutting-edge pharmacological molecules to improve the therapeutic process. According to Statista, the prevalence of chronic obstructive pulmonary disease in the United States is expected to increase to around 11.6% among adults by the year 2050. Asia Pacific is expected to grow significantly during the forecast period, owing to an increase in biotechnology research and center activity in the market space.

Major market players included in this report are:
F. Hoffmann-La Roche Ltd
Bayer AG
Sun Pharmaceutical Industries Ltd
Novartis AG
Drägerwerk AG & Co. KGaA
Fisher & Paykel Healthcare Limited
LivaNova PLC
Besmed Health Business Corp
Armstrong Medical
Pfizer Inc.

Recent Developments in the Market:
In April 2022, Novartis Pharma introduced Egypt's first fixed dose combination triple therapy in one device for asthma, with the purpose of enhancing patients' management as well as their quality of life.

Global Acute Respiratory Distress Syndrome Treatment Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Drug Class, Route of Administration, Distribution Channel, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drug Class

Vasoconstrictors
Bronchodilators
Steroids and Antibiotics
Others

By Route of Administration

Oral
Injection
Inhalation


By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
F. Hoffmann-La Roche Ltd
Bayer AG
Sun Pharmaceutical Industries Ltd
Novartis AG
Drägerwerk AG & Co. KGaA
Fisher & Paykel Healthcare Limited
LivaNova PLC
Besmed Health Business Corp
Armstrong Medical
Pfizer Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.